Tocilizumab injection
Products billed under this code include Actemra.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Actemra.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Actemra | Genentech, Inc. | 50242-0135-01 | 80 | $426.00 |
| Actemra | Genentech, Inc. | 50242-0136-01 | 200 | $1,065.00 |
| Actemra | Genentech, Inc. | 50242-0137-01 | 400 | $2,130.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5.325 | −$0.083 | 1 MG | Tocilizumab injection | v1, posted September 17, 2026 |
| 3Q26 | $5.408 | −$0.122 | 1 MG | Tocilizumab injection | v1, posted September 15, 2026 |
| 2Q26 | $5.53 | −$0.079 | 1 MG | Tocilizumab injection | v1, posted September 15, 2026 |
| 1Q26 | $5.609 | −$0.099 | 1 MG | Tocilizumab injection | v1, posted September 15, 2026 |
| 4Q25 | $5.708 | −$0.078 | 1 MG | Tocilizumab injection | v1, posted September 8, 2026 |
| 3Q25 | $5.786 | −$0.095 | 1 MG | Tocilizumab injection | v1, posted March 10, 2026 |
| 2Q25 | $5.881 | −$0.085 | 1 MG | Tocilizumab injection | v1, posted March 10, 2026 |
| 1Q25 | $5.966 | +$0.004 | 1 MG | Tocilizumab injection | v1, posted December 19, 2025 |
| 4Q24 | $5.962 | +$0.012 | 1 MG | Tocilizumab injection | v1, posted June 11, 2025 |
| 3Q24 | $5.95 | −$0.092 | 1 MG | Tocilizumab injection | v1, posted June 11, 2025 |
| 2Q24 | $6.042 | −$0.078 | 1 MG | Tocilizumab injection | v1, posted March 11, 2025 |
| 1Q24 | $6.12 | −$0.068 | 1 MG | Tocilizumab injection | v1, posted December 19, 2024 |
| 4Q23 | $6.188 | +$0.278 | 1 MG | Tocilizumab injection | v1, posted October 10, 2024 |
| 3Q23 | $5.91 | +$0.05 | 1 MG | Tocilizumab injection | v1, posted June 5, 2024 |
| 2Q23 | $5.86 | −$0.129 | 1 MG | Tocilizumab injection | v1, posted February 23, 2024 |
| 1Q23 | $5.989 | −$0.175 | 1 MG | Tocilizumab injection | v1, posted December 6, 2023 |
| 4Q22 | $6.164 | +$0.366 | 1 MG | Tocilizumab injection | v1, posted June 22, 2023 |
| 3Q22 | $5.798 | −$0.021 | 1 MG | Tocilizumab injection | v1, posted June 9, 2023 |
| 2Q22 | $5.819 | +$0.087 | 1 MG | Tocilizumab injection | v1, posted December 14, 2022 |
| 1Q22 | $5.732 | +$0.179 | 1 MG | Tocilizumab injection | v1, posted June 8, 2022 |
| 4Q21 | $5.553 | +$0.021 | 1 MG | Tocilizumab injection | v1, posted June 2, 2022 |
| 3Q21 | $5.532 | +$0.025 | 1 MG | Tocilizumab injection | v1, posted June 2, 2022 |
| 2Q21 | $5.507 | +$0.038 | 1 MG | Tocilizumab injection | v1, posted March 1, 2022 |
| 1Q21 | $5.469 | – | 1 MG | Tocilizumab injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.